SRPT

Sarepta Therapeutics, Inc.distress 2/10 · well-funded / low risk

$15.61-1%today-36% from 52w high

sarepta.com835 employeesFounded 1980Cambridge, MABiotechnology

Rare / Genetic 4

Lead: Duchenne Muscular Dystrophy · est. market ~$4B (approx, global)

Revenue

$731M

Liquidity

$735M

Runway

—

Shares 1y

+8%

Price & events

-28.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.4%

-9.4%

-9.6%

-23.6%

-26.1%

+17.2%

-89.4%

-76.6%

-90.6%

All

Overview

Market Cap: $1.65B
Enterprise Value: $2.02B
Volume: 172.95K
52 Week Range: $11.93 – $24.45
Total Shares: 105.58M
Float Shares: 94.61M
Short %: 32.62%
% Held by Insiders: 4.22%
% Held by Institutions: 99.62%
RVOL: 0.05x
Beta: 0.20

Pipeline stages · 3 programs

Eteplirsen

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-10-31

delandistrogene moxeparvovec

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-05-31

SRP-9004

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 7 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-10-31 Estimated 50% readout ~2027-01-14	Phase 3	Eteplirsen	Muscular Dystrophy, Duchenne	—	active not recruiting
2027-05-31 Estimated 50% readout ~2027-08-14	Phase 3	delandistrogene moxeparvovec	Duchenne Muscular Dystrophy	—	active not recruiting
2033-10-31 Estimated 50% readout ~2034-01-14	Phase 3	delandistrogene moxeparvovec	Duchenne Muscular Dystrophy	—	enrolling by invitation
2025-10-10	Phase 1	delandistrogene moxeparvovec, imlifidase	Duchenne Muscular Dystrophy	5	terminated
2025-06-18	Phase 1	SRP-9004	Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3	4	terminated

Show all 7 trials · 2 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2025-03-04	Phase 3	SRP-9003, Glucocorticoid	Limb-girdle Muscular Dystrophy	17	active not recruiting
2025-01-14	Phase 1/2	SRP-9003	Limb-Girdle Muscular Dystrophy, Type 2E	6	terminated